Recent Progresses in the Treatment of Osteoporosis
Osteoporosis (OP) is a chronic bone disease characterized by aberrant microstructure and macrostructure of bone, leading to reduced bone mass and increased risk of fragile fractures. Anti-resorptive drugs, especially, bisphosphonates, are currently the treatment of choice in most developing countrie...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-07-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.717065/full |
| _version_ | 1830132674064285696 |
|---|---|
| author | Shan-Shan Li Shi-Hao He Peng-Yu Xie Wei Li Xin-Xin Zhang Tian-Fang Li Dai-Feng Li Dai-Feng Li |
| author_facet | Shan-Shan Li Shi-Hao He Peng-Yu Xie Wei Li Xin-Xin Zhang Tian-Fang Li Dai-Feng Li Dai-Feng Li |
| author_sort | Shan-Shan Li |
| collection | DOAJ |
| description | Osteoporosis (OP) is a chronic bone disease characterized by aberrant microstructure and macrostructure of bone, leading to reduced bone mass and increased risk of fragile fractures. Anti-resorptive drugs, especially, bisphosphonates, are currently the treatment of choice in most developing countries. However, they do have limitations and adverse effects, which, to some extent, helped the development of anabolic drugs such as teriparatide and romosozumab. In patients with high or very high risk for fracture, sequential or combined therapies may be considered with the initial drugs being anabolic agents. Great endeavors have been made to find next generation drugs with maximal efficacy and minimal toxicity, and improved understanding of the role of different signaling pathways and their crosstalk in the pathogenesis of OP may help achieve this goal. Our review focused on recent progress with regards to the drug development by modification of Wnt pathway, while other pathways/molecules were also discussed briefly. In addition, new observations made in recent years in bone biology were summarized and discussed for the treatment of OP. |
| first_indexed | 2024-12-17T06:39:39Z |
| format | Article |
| id | doaj.art-eceb0f79b2a84a2fb823aa121b3399a8 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-17T06:39:39Z |
| publishDate | 2021-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-eceb0f79b2a84a2fb823aa121b3399a82022-12-21T21:59:54ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-07-011210.3389/fphar.2021.717065717065Recent Progresses in the Treatment of OsteoporosisShan-Shan Li0Shi-Hao He1Peng-Yu Xie2Wei Li3Xin-Xin Zhang4Tian-Fang Li5Dai-Feng Li6Dai-Feng Li7Department of Rheumatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Rheumatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Rheumatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Rheumatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Rheumatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Rheumatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Orthopaedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Magnetic Resonance Imaging, Henan Key Laboratory of Functional Magnetic Resonance Imaging and Molecular Imaging, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaOsteoporosis (OP) is a chronic bone disease characterized by aberrant microstructure and macrostructure of bone, leading to reduced bone mass and increased risk of fragile fractures. Anti-resorptive drugs, especially, bisphosphonates, are currently the treatment of choice in most developing countries. However, they do have limitations and adverse effects, which, to some extent, helped the development of anabolic drugs such as teriparatide and romosozumab. In patients with high or very high risk for fracture, sequential or combined therapies may be considered with the initial drugs being anabolic agents. Great endeavors have been made to find next generation drugs with maximal efficacy and minimal toxicity, and improved understanding of the role of different signaling pathways and their crosstalk in the pathogenesis of OP may help achieve this goal. Our review focused on recent progress with regards to the drug development by modification of Wnt pathway, while other pathways/molecules were also discussed briefly. In addition, new observations made in recent years in bone biology were summarized and discussed for the treatment of OP.https://www.frontiersin.org/articles/10.3389/fphar.2021.717065/fullosteoporosisantiresorptive drugsanabolic drugswnt signaling pathwaybone formation |
| spellingShingle | Shan-Shan Li Shi-Hao He Peng-Yu Xie Wei Li Xin-Xin Zhang Tian-Fang Li Dai-Feng Li Dai-Feng Li Recent Progresses in the Treatment of Osteoporosis Frontiers in Pharmacology osteoporosis antiresorptive drugs anabolic drugs wnt signaling pathway bone formation |
| title | Recent Progresses in the Treatment of Osteoporosis |
| title_full | Recent Progresses in the Treatment of Osteoporosis |
| title_fullStr | Recent Progresses in the Treatment of Osteoporosis |
| title_full_unstemmed | Recent Progresses in the Treatment of Osteoporosis |
| title_short | Recent Progresses in the Treatment of Osteoporosis |
| title_sort | recent progresses in the treatment of osteoporosis |
| topic | osteoporosis antiresorptive drugs anabolic drugs wnt signaling pathway bone formation |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2021.717065/full |
| work_keys_str_mv | AT shanshanli recentprogressesinthetreatmentofosteoporosis AT shihaohe recentprogressesinthetreatmentofosteoporosis AT pengyuxie recentprogressesinthetreatmentofosteoporosis AT weili recentprogressesinthetreatmentofosteoporosis AT xinxinzhang recentprogressesinthetreatmentofosteoporosis AT tianfangli recentprogressesinthetreatmentofosteoporosis AT daifengli recentprogressesinthetreatmentofosteoporosis AT daifengli recentprogressesinthetreatmentofosteoporosis |